Citations

Mayo Clinic

Clear

279 citation(s) found for "Butler, J".

MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2
Gregory, Philip A. , Fernandes, Rayzel C. , Denis, Iza , Wang, Qingqing , Townley, Scott L. , Zhao, Shuang G. , Hanson, Adrienne R. , Pickering, Marie , Armstrong, Heather , Lokman, Noor A. , Ebrahimie, Esmaeil , Jenkins, Robert B. , Karnes, R. Jeffrey , Ross, Ashley E. , Den, Robert B. , Klein, Eric A. , Ramshaw, Hayley S. , Williams, Elizabeth D. , Zoubeidi, Amina , Goodall, Gregory J. , Feng, Felix Y. , Butler, Lisa M. , Tilley, Wayne D. , Selth, Luke A. , Das, Rajdeep , Townley, Scott L. , Zhao, Shuang G , Davicioni, Elai , N., Kim , Den, Robert B , Klein, Eric A

Cancer Research | December 23, 2016 | Volume: 77 | Issue: 4 | Pages: 1021-1034

10.1158/0008-5472.can-16-2529 | PMID 28011622 Get It

Abstract Serum levels of miR-194 have been reported to predict prostate cancer recurrence after surgery, but its functional contributions to this disease have not been studied. Herein, it is demonstrated that miR-194 is a driver of prostate cancer metastasis. Prostate tissue levels of miR-194 were associated with disease aggressiveness and poor outcome. Ectopic delivery of miR-194 stimulated migration, invasion, and epithelial–mesenchymal transition in human prostate cancer cell lines, and stable overexpression of miR-194 enhanced metastasis of intravenous and intraprostatic tumor xenografts. Conversely, inhibition of miR-194 activity suppressed the invasive capacity of prostate cancer cell lines in vitro and in vivo. Mechanistic investigations identified the ubiquitin ligase suppressor of cytokine signaling 2 (SOCS2) as a direct, biologically relevant target of miR-194 in prostate cancer. Low levels of SOCS2 correlated strongly with disease recurrence and metastasis in clinical specimens. SOCS2 downregulation recapitulated miR-194–driven metastatic phenotypes, whereas overexpression of a nontargetable SOCS2 reduced miR-194–stimulated invasion. Targeting of SOCS2 by miR-194 resulted in derepression of the oncogenic kinases FLT3 and JAK2, leading to enhanced ERK and STAT3 signaling. Pharmacologic inhibition of ERK and JAK/STAT pathways reversed miR-194–driven phenotypes. The GATA2 transcription factor was identified as an upstream regulator of miR-194, consistent with a strong concordance between GATA2 and miR-194 levels in clinical specimens. Overall, these results offer new insights into the molecular mechanisms of metastatic progression in prostate cancer. Cancer Res; 77(4); 1021–34. ©2016 AACR.
Oral Progestogens Versus Levonorgestrel-Releasing Intrauterine System for Treatment of Endometrial Intraepithelial Neoplasia
Marnach, Mary L. , Butler, Kristina , Henry, Michael , Hutz, Catherine E., Lohse, Christine M. , Casey, Petra M., Butler, Kristina A., Henry, Michael R, Langstraat, Carrie

Journal of Women's Health | November 30, 2016 | Volume: 26 | Issue: 4 | Pages: 368-373

10.1089/jwh.2016.5774 | PMID 27901412 Get It

Safety of intrathecal autologous adipose-derived mesenchymal stromal cells in patients with ALS
Staff, Nathan P. , Madigan, Nicolas N. , Jentoft, Mark E. , Sorenson, Eric J. , Butler, Greg W., Gastineau, Dennis A., Dietz, Allan B. , Windebank, Anthony J. , Jentoft, Mark, Butler, Greg, Gastineau, Dennis, Dietz, Allan, Morris, Jonathan M. , Gastineau, Dennis A. , Staff, Nathan P , Dietz, Allan B

Neurology | October 26, 2016 | Volume: 87 | Issue: 21 | Pages: 2230-2234

10.1212/wnl.0000000000003359 | PMID 27784774 Get It

Evaluation of a photon counting Medipix3RX CZT spectral x-ray detector
Jorgensen, Steven M., Vercnocke, Andrew J. , Rundle, David S., Butler, Philip H. , Ritman, Erik L., McCollough, Cynthia H.

SPIE Proceedings | October 3, 2016 | Volume: 9969 | Issue: No issue available | Pages: 99690J

10.1117/12.2236501 | PMID 27795606 Get It

Defining Glioblastoma Resectability Through the Wisdom of the Crowd: A Proof-of-Principle Study
Zacharia, Brad E. , Cloney, Michael , Sonabend, Aarón , Showers, Christopher R. , Ebiana, Victoria, Nazarian, Matthew , Swanson, Kristin R. , Baldock, Anne, Brem, Henry , Bruce, Jeffrey N. , Butler, William E. , Orringer, Daniel A. , Roberts, David W. , Sagher, Oren , Sanai, Nader , Schwartz, Theodore H. , Silbergeld, Daniel L. , Sisti, Michael B. , Thompson, Reid C., Waziri, Allen, Sonabend, Adam M , Swanson, Kristin R , Cahill, Daniel P. , Carter, Bob S. , Ghogawala, Zoher , McKhann, Guy M. , Zacharia, Brad E

Neurosurgery | August 10, 2016 | Volume: 80 | Issue: 4 | Pages: 590-601

10.1227/neu.0000000000001374 | PMID 27509070 Get It

Abstract BACKGROUND Extent of resection (EOR) correlates with glioblastoma outcomes. Resectability and EOR depend on anatomical, clinical, and surgeon factors. Resectability likely influences outcome in and of itself, but an accurate measurement of resectability remains elusive. An understanding of resectability and the factors that influence it may provide a means to control a confounder in clinical trials and provide reference for decision making. OBJECTIVE To provide proof of concept of the use of the collective wisdom of experienced brain tumor surgeons in assessing glioblastoma resectability. METHODS We surveyed 13 academic tumor neurosurgeons nationwide to assess the resectability of newly diagnosed glioblastoma. Participants reviewed 20 cases, including digital imaging and communications in medicine-formatted pre- and postoperative magnetic resonance images and clinical vignettes. The selected cases involved a variety of anatomical locations and a range of EOR. Participants were asked about surgical goal, eg, gross total resection, subtotal resection (STR), or biopsy, and rationale for their decision. We calculated a “resectability index” for each lesion by pooling responses from all 13 surgeons. RESULTS Neurosurgeons’ individual surgical goals varied significantly ( P = .015), but the resectability index calculated from the surgeons’ pooled responses was strongly correlated with the percentage of contrast-enhancing residual tumor ( R = 0.817, P < .001). The collective STR goal predicted intraoperative decision of intentional STR documented on operative notes ( P < .01) and nonresectable residual ( P < .01), but not resectable residual. CONCLUSION In this pilot study, we demonstrate the feasibility of measuring the resectability of glioblastoma through crowdsourcing. This tool could be used to quantify resectability, a potential confounder in neuro-oncology clinical trials.
Fine needle aspiration cytology of cervical lymph node involvement by ovarian serous borderline tumor
Butler, Kristina , Bell, Debra A., Chen, Longwen , Butler, Kristina A.

CytoJournal | July 26, 2016 | Volume: 13 | Issue: No issue available | Pages: 16

10.4103/1742-6413.187052 | PMID 27563339 Get It

Serous borderline tumor (SBT) involving a cervical lymph node is extremely rare. In addition, fine needle aspiration (FNA) cytology of the involved cervical lymph node shares tremendous morphologic similarity with other low-grade papillary carcinomas. Thus, it can be easily misdiagnosed as metastatic carcinoma. A 42-year-old female had a history of bilateral SBT and postbilateral salpingo-oophorectomy. She presented with left cervical lymphadenopathy 6 months later. FNA cytology showed a low-grade papillary neoplasm with psammoma bodies. Needle core biopsy along with immunostains was diagnostic of cervical lymph node involvement (LNI) of SBT. although extremely rare, cervical LNI can be found in patients with SBTs. FNA cytology, sometimes, is indistinguishable from metastatic papillary adenocarcinoma. Cell block or needle core biopsy is essential to make the correct diagnosis.
Closure of a Recurrent Bronchopleural Fistula Using a Matrix Seeded With Patient-Derived Mesenchymal Stem Cells
Aho, Johnathon M. , Dietz, Allan B. , Radel, Darcie J., Butler, Greg W., Thomas, Mathew , Carlsen, Brian T. , Cassivi, Stephen D. , Resch, Zachary T., Faubion, William A. , Wigle, Dennis A. , Nelson, Timothy J. , Thomas, Mathew , Dietz, Allan B

Stem Cells Translational Medicine | June 25, 2016 | Volume: 5 | Issue: 10 | Pages: 1375-1379

10.5966/sctm.2016-0078 | PMID 27343169 Get It

Abstract Management of recurrent bronchopleural fistula (BPF) after pneumonectomy remains a challenge. Although a variety of devices and techniques have been described, definitive management usually involves closure of the fistula tract through surgical intervention. Standard surgical approaches for BPF incur significant morbidity and mortality and are not reliably or uniformly successful. We describe the first-in-human application of an autologous mesenchymal stem cell (MSC)-seeded matrix graft to repair a multiply recurrent postpneumonectomy BPF. Adipose-derived MSCs were isolated from patient abdominal adipose tissue, expanded, and seeded onto bio-absorbable mesh, which was surgically implanted at the site of BPF. Clinical follow-up and postprocedural radiological and bronchoscopic imaging were performed to ensure BPF closure, and in vitro stemness characterization of patient-specific MSCs was performed. The patient remained clinically asymptomatic without evidence of recurrence on bronchoscopy at 3 months, computed tomographic imaging at 16 months, and clinical follow-up of 1.5 years. There is no evidence of malignant degeneration of MSC populations in situ, and the patient-derived MSCs were capable of differentiating into adipocytes, chondrocytes, and osteocytes using established protocols. Isolation and expansion of autologous MSCs derived from patients in a malnourished, deconditioned state is possible. Successful closure and safety data for this approach suggest the potential for an expanded study of the role of autologous MSCs in regenerative surgical applications for BPF. Significance Bronchopleural fistula is a severe complication of pulmonary resection. Current management is not reliably successful. This work describes the first-in-human application of an autologous mesenchymal stem cell (MSC)-seeded matrix graft to the repair of a large, multiply recurrent postpneumonectomy BPF. Clinical follow-up of 1.5 years without recurrence suggests initial safety and feasibility of this approach. Further assessment of MSC grafts in these difficult clinical scenarios requires expanded study.
The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group
Geyer, Holly L. , Andréasson, Björn , Dueck, Amylou C. , Scherber, Robyn M. , Martin, Kari A. , Butler, Kristina , Harrison, Claire , Radia, Deepti , Cervantes, Francisco , Kiladjian, Jean‐Jacques , Reiter, Andreas , Birgegård, Gunnar , Passamonti, Francesco , Senyak, Zhenya, Xiao, Zhijian , Samuelsson, Jan , Butler, Kristina A., Dueck, A. C. , Kosiorek, Heidi , Vannucchi, Alessandro M. , Paoli, Chiara , Mesa, Ruben A. , Kiladjian, Jean-Jacques , Passamonti, Francesco

Cancer | April 12, 2016 | Volume: 122 | Issue: 12 | Pages: 1888-1896

10.1002/cncr.30013 | PMID 27070130 Get It

BACKGROUNDPatients with myeloproliferative neoplasms (MPNs) including polycythemia vera, essential thrombocythemia, and myelofibrosis, are faced with oppressive symptom profiles that compromise daily functioning and quality of life. Among these symptoms, sexuality‐related symptoms have emerged as particularly prominent and largely unaddressed. In the current study, the authors evaluated how sexuality symptoms from MPN relate to other patient characteristics, disease features, treatments, and symptoms.METHODSA total of 1971 patients with MPN (827 with essential thrombocythemia, 682 with polycythemia vera, 456 with myelofibrosis, and 6 classified as other) were prospectively evaluated and patient responses to the Myeloproliferative Neoplasm Symptom Assessment Form (MPN‐SAF) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC‐QLQ C30) were collected, along with information regarding individual disease characteristics and laboratory data. Sexuality scores were compared with an age‐matched, healthy control population.RESULTSOverall, patients with MPN were found to have greater sexual dysfunction compared with the healthy population (MPN‐SAF score of 3.6 vs 2.0; P<.001), with 64% of patients with MPN describing some degree of sexual dysfunction and 43% experiencing severe symptoms. The presence of sexual symptoms correlated closely with all domains of patient functionality (physical, social, cognitive, emotional, and role functioning) and were associated with a reduced quality of life. Sexual problems also were found to be associated with other MPN symptoms, particularly depression and nocturnal and microvascular‐related symptoms. Sexual dysfunction was more severe in patients aged >65 years and in those with cytopenias and transfusion requirements, and those receiving certain therapies such as immunomodulators or steroids.ConclusionsThe results of the current study identify the topic of sexuality as a prominent issue for the MPN population, and this area would appear to benefit from additional investigation and management. Cancer 2016;122:1888–96. © 2016 American Cancer Society.
β-Cell Deficit in Obese Type 2 Diabetes, a Minor Role of β-Cell Dedifferentiation and Degranulation
Butler, Alexandra E. , Dhawan, Sangeeta , Hoang, Jonathan D. , Cory, Megan , Zeng, Kylie , Fritsch, Helga, Meier, Juris J. , Rizza, Robert A., Butler, Peter C. , Hoang, Jonathan, Dhawan, Sangeeta

The Journal of Clinical Endocrinology & Metabolism | December 23, 2015 | Volume: 101 | Issue: 2 | Pages: 523-532

10.1210/jc.2015-3566 | PMID 26700560 Get It

Abstract Context: Type 2 diabetes is characterized by a β-cell deficit and a progressive defect in β-cell function. It has been proposed that the deficit in β-cells may be due to β-cell degranulation and transdifferentiation to other endocrine cell types. Objective: The objective of the study was to establish the potential impact of β-cell dedifferentiation and transdifferentiation on β-cell deficit in type 2 diabetes and to consider the alternative that cells with an incomplete identity may be newly forming rather than dedifferentiated. Design, Setting, and Participants: Pancreata obtained at autopsy were evaluated from 14 nondiabetic and 13 type 2 diabetic individuals, from four fetal cases, and from 10 neonatal cases. Results: Whereas there was a slight increase in islet endocrine cells expressing no hormone in type 2 diabetes (0.11 ± 0.03 cells/islet vs 0.03 ± 0.01 cells/islet, P &lt; .01), the impact on the β-cell deficit would be minimal. Furthermore, we established that the deficit in β-cells per islet cannot be accounted for by an increase in other endocrine cell types. The distribution of hormone negative endocrine cells in type 2 diabetes (most abundant in cells scattered in the exocrine pancreas) mirrors that in developing (embryo and neonatal) pancreas, implying that these may represent newly forming cells. Conclusions: Therefore, although we concur that in type 2 diabetes there are endocrine cells with altered cell identity, this process does not account for the deficit in β-cells in type 2 diabetes but may reflect, in part, attempted β-cell regeneration.